The Medicines (MDCO) Upgraded at ValuEngine

ValuEngine upgraded shares of The Medicines (NASDAQ:MDCO) from a sell rating to a hold rating in a research report released on Friday.

A number of other research analysts have also commented on MDCO. Cowen reaffirmed a buy rating and set a $54.00 price objective (down previously from $61.00) on shares of The Medicines in a research report on Thursday, August 10th. TheStreet lowered shares of The Medicines from a c- rating to a d rating in a research report on Wednesday, August 9th. Jefferies Group reaffirmed a buy rating and set a $54.00 price objective (down previously from $62.00) on shares of The Medicines in a research report on Thursday, August 10th. Oppenheimer raised shares of The Medicines from a market perform rating to a buy rating and set a $50.00 price objective for the company in a research report on Wednesday, November 29th. Finally, Citigroup raised shares of The Medicines from a sell rating to an outperform rating in a research report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $53.67.

The Medicines (NASDAQ MDCO) opened at $28.18 on Friday. The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42. The Medicines has a 52-week low of $27.77 and a 52-week high of $55.95.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.95. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share. analysts expect that The Medicines will post -8.86 earnings per share for the current fiscal year.

In other The Medicines news, Director Alexander J. Denner purchased 170,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the transaction, the director now directly owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 8.22% of the company’s stock.

A number of large investors have recently bought and sold shares of MDCO. Zurcher Kantonalbank Zurich Cantonalbank raised its position in The Medicines by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after purchasing an additional 264 shares in the last quarter. Quantbot Technologies LP acquired a new position in The Medicines in the third quarter worth about $171,000. First Mercantile Trust Co. grew its stake in The Medicines by 2.5% during the second quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after buying an additional 114 shares during the last quarter. SG Americas Securities LLC bought a new stake in The Medicines during the third quarter worth about $198,000. Finally, Bluefin Trading LLC bought a new stake in The Medicines during the second quarter worth about $214,000.

TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/05/the-medicines-mdco-upgraded-at-valuengine.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

What are top analysts saying about The Medicines Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit